The European Union has granted CE mark approval to Boston Scientific’s spinal cord stimulator (SCS) system, designed to provide improved pain relief in chronic pain patients.
The Precision Spectra system, which the company claims is the world’s first and only SCS system with 32 contacts and 32 dedicated power sources, has four lead ports that offer more coverage of the spinal cord for the management of chronic pain.
The lead ports provide physicians with more flexibility to treat patients’ pain at time of implant and adapt to changing pain patterns in the future.
Equipped with an implantable pulse generator, the SCS delivers electrical pulses to leads with stimulating contacts and mask pain signals travelling to the brain.
To study the efficacy of the system, the first implant was performed at the Basildon and Thurrock University Hospitals in the UK.
Basildon and Thurrock University Hospitals pain medicine and neuromodulation consultant Dr Simon Thomson said previously, the SCS system was having four to eight contacts.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Now, by doubling the number of contacts to 32 while providing a dedicated power source for each contact, the Precision Spectra System advances our ability to provide pain relief,” Thomson added.
To further characterise the benefits of 32 contact option in Precision Spectra, the company has begun a prospective, multi-centre, single arm study named OPTIONS trial.
Boston Scientific has initiated a cross-sectional, multicentre MAP trial to identify the prevalence of multiple areas of pain in SCS-eligible patients with certain diseases.
Boston Scientific said that the new SCS system is currently under review by the US Food and Drug Administration and is not available for sale in the US.
Image: Boston Scientific’s corporate headquarters in Natick, Massachusetts, US. Photo: courtesy of BostonScientific.